Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 13/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FRK | P42685 | 1/20 | 0.55 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.55 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | LDHB | P07195 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473531 | 1.00 | CSF1R (0.58) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL3474925 | 0.84 | CSF1R (0.63) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL3560403 | 0.84 | CSF1R (0.58) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL1679423 | 0.84 | CSF1R (0.58) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL13313078 | 0.84 | CSF1R (0.58) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL14705857 | 0.83 | CSF1R (0.48) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL1679576 | 0.83 | CSF1R (0.62) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL1678955 | 0.83 | CSF1R (0.62) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL1991252 | 0.83 | CSF1R (0.62) | CSF1RRETPDGFRBKITSRC | |
| SCHEMBL19447153 | 0.83 | CSF1R (0.67) | CSF1RRETPDGFRBKITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848610-B1 | Inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-2848610-B1 | Inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-10-11 | — | — | EP | disclosed |
| EP-3048099-A2 | INHIBITORS OF KINASE ACTIVITY | YM BioSciences Australia Pty Ltd (AU) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048099-A2 | INHIBITORS OF KINASE ACTIVITY | YM BioSciences Australia Pty Ltd (AU) | 2016-07-27 | — | — | EP | disclosed |
| US-9029386-B2 | Pyridine derivatives useful as kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029386-B2 | Pyridine derivatives useful as kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2848610-A1 | Inhibitors of kinase activity | YM BioSciences Australia Pty Ltd (AU) | 2015-03-18 | — | — | EP | disclosed |
| EP-2848610-A1 | Inhibitors of kinase activity | YM BioSciences Australia Pty Ltd (AU) | 2015-03-18 | — | — | EP | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-8461161-B2 | Substituted pyrazines as inhibitors of kinase activity | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-06-11 | — | — | US | disclosed |
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-05-30 | — | — | US | disclosed |
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-05-30 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137660-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | CSF1R 62/4885RET 4/4885PDGFRB 97/4885 |
| US-20100130447-A1 | INHIBITORS OF KINASE ACTIVITY | FRK, LCK, FLT3 | CSF1R 62/4885RET 4/4885PDGFRB 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.